Therapeutic Drug Monitoring of Immunosuppressant Drugs by High-Performance Liquid Chromatography-Mass Spectrometry

Therapeutic Drug Monitoring

Volumn 26, Issue 2, 2004, Pages 215-219

  Taylor, Paul J ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Immunosuppression; Mass spectrometry; Therapeutic drug monitoring; Transplantation

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ATMOSPHERIC PRESSURE; AUTOMATION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IONIZATION; LOW DRUG DOSE; MASS SPECTROMETRY; PRIORITY JOURNAL; SAMPLE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SOLID PHASE EXTRACTION; TRANSPLANTATION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MACROLIDES; MASS SPECTROMETRY; MYCOPHENOLIC ACID; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 14844305229     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200404000-00023     Document Type: Conference Paper

References (54)

1. Kahan BD, Shaw LM, Holt D, et al. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem. 1990;36:1510-1516.
2. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens. 2002;11:657-663.
3. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation. 2002;73:920-925.
4. Stepkowski SM, Tian L, Napoli KL, et al. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. Clin Exp Immunol. 1997;108:63-68.
5. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 1997;64:32-35.
6. Vu DM, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation. 1997;64:1853-1856.
7. Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation. 1999;68:1526-1532.
8. McAlister VC, Gao ZH, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet. 2000;355:376-377.
9. Lo A, Alloway RR. Strategies to reduce toxicities and improve outcomes in renal transplant recipients. Pharmacotherapy. 2002;22:316-328.
10. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventative strategies. Curr Opin Crit Care. 2001;7:384-389.
11. Covey TR, Lee ED, Bruins AP, et al. Liquid chromatography/mass spectrometry. Anal Chem. 1986;58:1451A-1461A.
12. Siuzdak G. The emergence of mass spectrometry in biochemical research. Proc Natl Acad Sci USA. 1994;91:11290-11297.
13. Bruins AP, Covey TR, Henion JD. Ion spray interface for combined liquid chromatography/atmospheric pressure ionization mass spectrometry. Anal Chem. 1987;59:2642-2646.
14. Gaskell SJ. Electrospray: principles andpractice. JMass Spectrom. 1997;32:677-688.
15. Siuzdak G. Mass analyzers and detectors. In: Mass Spectrometry for Biotechnology. San Diego: Academic Press, 1996:32-55.
16. Oliveria EJ, Watson DG. Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics. Biomed Chromatogr. 2000;14:351-372.
17. Brewer E, Henion J. Atmospheric pressure ionization LC/MS/MS techniques for drug disposition studies. J Pharm Sci. 1998;87:395-402.
18. Deters M, Kaever V, Kirchner GI. Liquid chromatography/mass spectrometry for therapeutic drug monitoring of immunosuppressants. Anal Chim Acta. 2003;492:133-145.
19. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit. 1995;17:642-654.
20. Shaw LM, Holt DW, Keown P, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther. 1999;21:1632-1652.
21. Whitman DA, Abbott V, Fregien K, et al. Recent advances in high-performance liquid chromatography/mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry: detection of cyclosporine and metabolites in kidney and liver tissue. Ther Drug Monit. 1993;15:552-556.
22. Taylor PJ, Jones CE, Martin PT, et al. Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood. J Chromatogr B Biomed Sci Appl. 1998;705:289-294.
23. 2-monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs. 2001;15:279-290.
24. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24:330-350.
25. Holt DW, Johnston A, Kahan BD, et al. New approaches to cyclosporin monitoring raise further concerns about analytical techniques. Clin Chem. 2000;46:872-874.
26. Keevil BG, Tierney DP, Cooper DP, et al. Rapid liquid chromatography-tandem mass spectrometry for routine analysis of cyclosporin A over an extended concentration range. Clin Chem. 2002;48:67-76.
27. Keevil BG, Tierney DP, Cooper DP, et al. Simultaneous and rapid analysis of cyclosporin A and creatinine in finger prick blood samples using liquid chromatography tandem mass spectrometry and its application to C2 monitoring. Ther Drug Monit. 2002;24:757-767.
28. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001;34:9-16.
29. Holt DW, Armstrong VW, Griesmacher A, et al. International Federation of Clinical Chemistry/Intemational Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit. 2002;24:59-67.
30. Gonschior A-K, Christians U, Winkler M, et al. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. Ther Drug Monit. 1995;17:504-510.
31. Streit F, Christians U, Schiebel HM, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 1996;42:1417-1425.
32. Taylor PJ, Jones A, Balderson GA, et al. Sensitive, specific quantitation of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin Chem. 1996;42:279-285.
33. Zhang Q, Simpson J, Aboleneen HI. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. Ther Drug Monit. 1997;19:470-476.
34. Alak AM, Moy S, Cook M, et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. J Pharm Biomed Anal. 1997;16:7-13.
35. Segarra I, Brazelton TR, Guterman N, et al. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. J Chromatogr B Biomed Sci Appl. 1998;720:179-187.
36. Brignol N, McMahon LM, Luo S, et al. High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood. Rapid Commun Mass Spectrom. 2001;15:898-907.
37. Lensmeyer GL, Poquette MA. Therapeutic monitoring of tacrolimus concentrations in blood: semi-automated extraction and liquid chromatography-electrospray ionization mass spectrometry. Ther Drug Monit. 2001;23:239-249.
38. Vogeser M, Fleischer C, Meiser B, et al. Quantification of sirolimus by liquid chromatography-tandem mass spectrometry using on-line solidphase extraction. Clin Chem Lab Med. 2002;40:40-45.
39. Salm P, Taylor PJ, Lynch SV, et al. Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772:283-290.
40. Keevil BG, McCann SJ, Cooper DP, et al. Evaluation of a rapid microscale assay for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem. 2002;39:487-492.
41. Holt DW, Lee T, Jones K, et al. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem. 2000;46:1179-1183.
42. Annesley TM. Ion suppression in mass spectrometry. Clin Chem. 2003;49:1041-1044.
43. Xia YQ, Whigan DB, Powell ML, et al. Ternary-column system for high-throughput direct-injection bioanalysis by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2000;14:105-111.
44. Vidal C, Kirchner GI, Wunsch G, et al. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection. Clin Chem. 1998;44:1275-1282.
45. Taylor PJ, Salm P, Lynch SV, et al. Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2000;22:608-612.
46. Christians U, Jacobsen W, Serkova N, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl. 2000;748:41-53.
47. McMahon LM, Luo S, Hayes M, et al. High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system. Rapid Commun Mass Spectrom. 2000;14:1965-1971.
48. Volosov A, Napoli KL, Soldin SJ. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry. Clin Biochem. 2001;34:285-290.
49. Deters M, Kirchner G, Resch K, et al. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). Clin Chem Lab Med. 2002;40:285-292.
50. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem. 2002;48:955-958.
51. Atcheson B, Taylor PJ, Pillans PI, et al. Measurement of free drug and clinical endpoint by high-performance liquid chromatography/mass spectrometry: Applications and implications for pharmacokinetic and pharmacodynamic studies. Anal Chim Acta. 2003;492:157-169.
52. Willis C, Taylor PJ, Salm P, et al. Quantification of free mycophenolic acid by high-performance liquid chromatography-atmospheric pressure chemical ionisation tandem mass spectrometry. J Chromatogr B. 2000;748:151-156.
53. Braun F, Schutz E, Christians U, et al. Pitfalls in monitoring tacrolimus (FK 506). Ther Drug Monit. 1997;19:628-631.
54. Salm P, Taylor PJ, Pillans PI. The quantification of sirolimus by HPLC-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients. Clin Ther. 2000;22(Suppl B):B71-B85.